Serpin A1

Serpin A1 Molekülinformation

Englischer NameAlpha-1-antiproteinaseAnzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel14Target-AliasAlpha-1-antiproteinase,PRO2209,Serpin Family A Member 1,alpha 1-Antitrypsin,Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin,Alpha-1 Protease Inhibitor,Serpin A1,AAT,PI,Serpin Peptidase Inhibitor Clade A (Alpha-1antiproteinase, Antitrypsin) Member 1,Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 1,Alpha-1-Antitrypsin Short Transcript Variant 1C4,Serpin Peptidase Inhibitor Clade A Member 1,Alpha-1-Antitrypsin Null,Alpha-1 Antitrypsin,Alpha-1-Antitrypsin,Alpha1AT,PRO2275,NNIF,A1A,PI1,Epididymis Secretory Sperm Binding Protein,Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1,Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1,Alpha-1-Antitrypsin Short Transcript Variant 1C5,A1AT,PRO0684,SPAAT,SERPINA1
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameAlpha-1-antiproteinase
Target-AliasAlpha-1-antiproteinase,PRO2209,Serpin Family A Member 1,alpha 1-Antitrypsin,Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin,Alpha-1 Protease Inhibitor,Serpin A1,AAT,PI,Serpin Peptidase Inhibitor Clade A (Alpha-1antiproteinase, Antitrypsin) Member 1,Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 1,Alpha-1-Antitrypsin Short Transcript Variant 1C4,Serpin Peptidase Inhibitor Clade A Member 1,Alpha-1-Antitrypsin Null,Alpha-1 Antitrypsin,Alpha-1-Antitrypsin,Alpha1AT,PRO2275,NNIF,A1A,PI1,Epididymis Secretory Sperm Binding Protein,Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1,Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1,Alpha-1-Antitrypsin Short Transcript Variant 1C5,A1AT,PRO0684,SPAAT,SERPINA1
Anzahl der inverkehr gebrachten Arzneimittel2
Anzahl der klinischen Arzneimittel14
Höchste Forschungs- und EntwicklungsphaseApproved

Serpin A1 Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaften
Human
HEK293
Human Serpin A1 Protein, His Tag
Gesamtmenge1
  • 1

Serpin A1 Molekülhintergrund

Serpin A1 is also known as Alpha-1-antitrypsin (A1AT), serum trypsin inhibitor, alpha-1 proteinase inhibitor (A1PI), AAT, which belongs to the serpin family. Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Serpin A1 / A1AT is inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form of SerpinA1 inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Serpin A1 / A1AT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD).

Serpin A1 Molekülalias

SerpinA1,PI,A1A,AAT,PI1,A1AT,MGC9222,PRO2275,MGC23330,alpha1AT,SPAAT

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
FazirsiranTAK-999; ADS-001; ARO-AATPhase 3 ClinicalArrowhead Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltdalpha 1-Antitrypsin Deficiency; Hepatic Insufficiency
Details
YOLT-202YOLT-202Phase 3 ClinicalShanghai Yaotang Biotechnology Co Ltdalpha 1-Antitrypsin Deficiency; Genetic Diseases, Inborn
Details
Efdoralprin alfaINBRX-101; AT-292; rhAAT-Fc; AAT-IgG-Fc; AAT-Fc; SAR447537; SAR-447537Phase 2 ClinicalArecor Ltd, Inhibrxalpha 1-Antitrypsin Deficiency; Emphysema
Details
TSRA-196TSRA-196Phase 2 ClinicalTessera Therapeutics Incalpha 1-Antitrypsin Deficiency
Details
VX-864VX-864Phase 2 ClinicalVertex Pharmaceuticals Incorporatedalpha 1-Antitrypsin Deficiency
Details
KRRO-110KRRO-110Phase 2 ClinicalKorro Bio Incalpha 1-Antitrypsin Deficiency
Details
WVE-006WVE-006; GSK-5462688Phase 2 ClinicalWave Life Sciences Ltdalpha 1-Antitrypsin Deficiency
Details
BEAM-302α1-AD; α-1-AD; BEAM-302Phase 2 ClinicalBeam Therapeutics Incalpha 1-Antitrypsin Deficiency
Details
adeno-associated virus gene therapy (University of Massachusetts/University of Florida/NHLBI)Phase 1 ClinicalUniversity of Massachusettsalpha 1-Antitrypsin Deficiency
Details
KB-408KB-408Phase 1 ClinicalKrystal Biotech Incalpha 1-Antitrypsin Deficiency
Details
VX-668VX-668; VX668Phase 1 ClinicalVertex Pharmaceuticals Incorporatedalpha 1-Antitrypsin Deficiency
Details
VX-634VX-634Phase 1 ClinicalVertex Pharmaceuticals Incorporatedalpha 1-Antitrypsin Deficiency
Details
BMN-349BMN-349Phase 1 ClinicalBiomarin Pharmaceutical Incalpha 1-Antitrypsin Deficiency
Details
Alpha-1 antitrypsin (Kalytera Therapeutics)ClinicalClalit Health Services
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Alpha1-proteinase inhibitor (Human, Grifols)TAL-6004ApprovedBayer AG, Grifols SaProlastin, Prolastin-cUnited Statesalpha 1-Antitrypsin Deficiencynull1987-12-02alpha 1-Antitrypsin Deficiency; Coronavirus Disease 2019 (COVID-19); Cystic Fibrosis; Pancreatitis, Chronic; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema
Details
Alfalastin (LFB SA)ApprovedLfb Biotechnologies SasAlfalastinFrancealpha 1-Antitrypsin DeficiencyLfb Biotechnologies Sas2005-08-01alpha 1-Antitrypsin Deficiency
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns